Investigative Ophthalmology & Visual Science Cover Image for Volume 60, Issue 9
July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Stem-cell based therapy for dry AMD
Author Affiliations & Notes
  • Amir H. Kashani
    Ophthalmology, University of Southern California, Los Angeles, California, United States
    USC Roski Eye Institute, Los Angeles, California, United States
  • Footnotes
    Commercial Relationships   Amir Kashani, Carl Zeiss Meditec (F), Carl Zeiss Meditec (R), Regenerative Patch Technologies (F)
  • Footnotes
    Support  Regenerative Patch Technologies, California Institute for Regenerative Medicine
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 2201. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Amir H. Kashani; Stem-cell based therapy for dry AMD. Invest. Ophthalmol. Vis. Sci. 2019;60(9):2201.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Presentation Description : Severe vision loss from geographic atrophy (GA) and advanced dry age-related macular degeneration (AMD) is a major unmet medical need. Cell-based replacement strategies are a potential method of repairing the loss of retinal pigment epithelium (RPE) that is characteristic of GA and also restoring vision or preventing further vision loss. We have performed a phase 1/2a clinical trial of a novel stem cell derived replacement strategy utilizing a monolayer of mature, polarized RPE. In this presentation we will summarize the preclinical and clinical results of this study.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×